JP2022526398A5 - - Google Patents

Info

Publication number
JP2022526398A5
JP2022526398A5 JP2021558847A JP2021558847A JP2022526398A5 JP 2022526398 A5 JP2022526398 A5 JP 2022526398A5 JP 2021558847 A JP2021558847 A JP 2021558847A JP 2021558847 A JP2021558847 A JP 2021558847A JP 2022526398 A5 JP2022526398 A5 JP 2022526398A5
Authority
JP
Japan
Application number
JP2021558847A
Other languages
Japanese (ja)
Other versions
JPWO2020210542A5 (https=
JP2022526398A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027541 external-priority patent/WO2020210542A1/en
Publication of JP2022526398A publication Critical patent/JP2022526398A/ja
Publication of JP2022526398A5 publication Critical patent/JP2022526398A5/ja
Publication of JPWO2020210542A5 publication Critical patent/JPWO2020210542A5/ja
Priority to JP2025023769A priority Critical patent/JP2025084803A/ja
Pending legal-status Critical Current

Links

JP2021558847A 2019-04-09 2020-04-09 標的化されたIn vivoエピジェネティック抑制を介した持続性鎮痛剤 Pending JP2022526398A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023769A JP2025084803A (ja) 2019-04-09 2025-02-17 標的化されたIn vivoエピジェネティック抑制を介した持続性鎮痛剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962831706P 2019-04-09 2019-04-09
US62/831,706 2019-04-09
US201962877810P 2019-07-23 2019-07-23
US62/877,810 2019-07-23
PCT/US2020/027541 WO2020210542A1 (en) 2019-04-09 2020-04-09 Long-lasting analgesia via targeted in vivo epigenetic repression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023769A Division JP2025084803A (ja) 2019-04-09 2025-02-17 標的化されたIn vivoエピジェネティック抑制を介した持続性鎮痛剤

Publications (3)

Publication Number Publication Date
JP2022526398A JP2022526398A (ja) 2022-05-24
JP2022526398A5 true JP2022526398A5 (https=) 2023-02-27
JPWO2020210542A5 JPWO2020210542A5 (https=) 2023-02-27

Family

ID=72750870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558847A Pending JP2022526398A (ja) 2019-04-09 2020-04-09 標的化されたIn vivoエピジェネティック抑制を介した持続性鎮痛剤
JP2025023769A Pending JP2025084803A (ja) 2019-04-09 2025-02-17 標的化されたIn vivoエピジェネティック抑制を介した持続性鎮痛剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023769A Pending JP2025084803A (ja) 2019-04-09 2025-02-17 標的化されたIn vivoエピジェネティック抑制を介した持続性鎮痛剤

Country Status (7)

Country Link
US (1) US20220202957A1 (https=)
EP (2) EP4335925A3 (https=)
JP (2) JP2022526398A (https=)
KR (1) KR20210154176A (https=)
CN (1) CN113950526B (https=)
CA (1) CA3131759A1 (https=)
WO (1) WO2020210542A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505570A (ja) * 2021-02-01 2024-02-06 ナヴェガ セラピューティクス, インコーポレイテッド 神経学的疾患及び疼痛を治療するためのエピジェネティック遺伝子調節
US20220325298A1 (en) * 2021-04-12 2022-10-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Crispr epigenetic therapeutics for pain management
WO2023057880A1 (en) * 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Crispr/cas9-based fusion proteins for modulating gene expression and methods of use
WO2023114887A2 (en) * 2021-12-15 2023-06-22 The Trustees Of Indiana University Cell targeting compositions and methods
CN114317605B (zh) * 2022-03-11 2022-06-21 暨南大学 一种小胶质细胞钾离子探针转基因小鼠模型的构建方法
KR20240030592A (ko) * 2022-08-31 2024-03-07 주식회사 아이엔테라퓨틱스 인비보 세포외 신경다발절 기록법을 이용한 전기생리학적 약효평가법
KR20250128349A (ko) * 2022-12-23 2025-08-27 에피제닉 테라퓨틱스 피티이 리미티드 융합체 및 이의 용도
KR20250124885A (ko) * 2022-12-23 2025-08-20 에피제닉 테라퓨틱스 피티이 리미티드 복합체 및 이의 용도
WO2025151796A1 (en) * 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025261493A1 (zh) * 2024-06-21 2025-12-26 益杰立科(上海)生物科技有限公司 通过表观编辑靶向调节pcsk9的方法及其用途
WO2025261475A1 (zh) * 2024-06-21 2025-12-26 益杰立科(上海)生物科技有限公司 靶向血管内皮生长因子的工程化基因转录阻抑工具及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JP4285766B2 (ja) 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2002057294A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger proteins for dna binding and gene regulation in plants
US20060246440A1 (en) * 2002-10-23 2006-11-02 Joung J K Methods for producing zinc finger proteins that bind to extended dna target sequences
JP2008506359A (ja) * 2004-04-08 2008-03-06 サンガモ バイオサイエンシズ インコーポレイテッド ジンクフィンガータンパク質による神経因性疼痛の処置
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
AU2009212247A1 (en) * 2008-02-08 2009-08-13 Sangamo Therapeutics, Inc. Treatment of chronic pain with zinc finger proteins
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CN108285491B (zh) * 2012-02-29 2021-08-10 桑格摩生物科学股份有限公司 治疗亨廷顿氏病的方法和组合物
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
AR095984A1 (es) * 2013-04-03 2015-11-25 Aliophtha Ag Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéutico
GB2544270A (en) * 2015-11-05 2017-05-17 Fundació Centre De Regulació Genòmica Nucleic acids, peptides and methods
WO2017083722A1 (en) * 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy
SG11201804814YA (en) * 2015-12-11 2018-07-30 Massachusetts Eye & Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
AU2017292173B2 (en) * 2016-07-06 2022-01-13 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
KR102547316B1 (ko) * 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2018035503A1 (en) * 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
WO2018156824A1 (en) * 2017-02-23 2018-08-30 President And Fellows Of Harvard College Methods of genetic modification of a cell
EP3592853A1 (en) * 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US20200255813A1 (en) * 2017-07-09 2020-08-13 Igc Bio, Inc. Pross optimized enzymes

Similar Documents

Publication Publication Date Title
JP2022526398A5 (https=)
CN305873204S (https=)
CN305916241S (https=)
CN305621250S (https=)
CN305537399S (https=)
CN305621071S (https=)
CN305536858S (https=)
CN305620999S (https=)
CN305536327S (https=)
CN305536202S (https=)
CN305617113S (https=)
CN305536100S (https=)
CN305865987S (https=)
CN305535153S (https=)
CN305534596S (https=)
CN305864055S (https=)
CN305615152S (https=)
CN305615019S (https=)
CN305614283S (https=)
CN305606303S (https=)
CN305604880S (https=)
CN305863707S (https=)
CN305603707S (https=)
CN305534348S (https=)
CN305602675S (https=)